PubMed · 2022

Cagrilintide, a long-acting amylin analogue, for the treatment of obesity

Lau DCW, Erondu N, Skovgaard D, et al. (2022). Cagrilintide, a long-acting amylin analogue, for the treatment of obesity. Lancet.

Lancet

Source: https://pubmed.ncbi.nlm.nih.gov/35894210/

Last reviewed July 14, 2026. By the PeptIQ team.

View original source

Peptides linked in PeptIQ Wiki

Cagrilintide — community report

This page indexes a published source for discovery and cross-linking. PeptIQ reports what the literature contains and what users track — it does not interpret studies as treatment guidance.